Friday 6 November 2026
Export BIO.B’s income statement to Excel — free account
Bio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.8%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
379.50
15.35
+4.22%
Follow BIO.B
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
11.12 | 45.54 | 35.59 | 9.57 |
P/S ratio |
3.28 | 2.90 | 3.06 | 3.77 | |
P/FCF ratio |
22.49 | 20.87 | 22.33 | 29.53 | |
P/Operating CF |
51.37 | 69.39 | 80.34 | 101.42 | |
P/B ratio |
1.14 | 1.09 | 1.11 | 1.29 | |
Price to Tangible BV |
1.26 | 1.23 | 1.23 | 1.41 | |
EV/Sales |
3.15 | 2.76 | 2.90 | 3.59 | |
EV/EBITDA |
172.31 | 123.95 | 141.53 | 0.00 | |
EV/Operating CF |
15.28 | 13.99 | 15.26 | 19.90 | |
EV/FCF |
21.59 | 19.87 | 21.16 | 28.14 | |
Quick Ratio |
3.87 | 2.17 | 2.14 | 2.15 | |
Current Ratio |
5.62 | 3.21 | 3.14 | 3.18 | |
Net Debt/EBITDA |
2.84 | (10.60) | (5.71) | 9.26 | |
Debt/Assets |
11.37% | 12.29% | 11.74% | 11.17% | |
Debt/Equity |
0.16 | 0.18 | 0.17 | 0.16 | |
Asset Turnover |
0.26 | 0.27 | 0.25 | 0.25 | |
Operating CF/Net income |
0.23 | (0.21) | 0.27 | 0.21 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(9.83) | 2.77 | 6.00 | (4.04) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 9.40% | 10.88% | |
Selling, General and Administrative Expense of Revenue |
31.88% | 35.87% | 32.57% | 39.17% | |
Intangible Assets out of Total Assets |
0.07 | 0.08 | 0.07 | 0.06 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.03) | 0.00 | (0.01) | (0.01) | |
Graham Number |
414.65 | 186.92 | 224.21 | 493.69 | |
Earnings Yield |
9.00% | 2.20% | 2.81% | 10.45% | |
Free Cash Flow Yield |
4.45% | 4.79% | 4.48% | 3.39% | |
Revenue per Share |
25.43 | 21.96 | 24.34 | 24.51 | |
Operating CF per Share |
6.05 | 4.01 | 3.69 | 3.60 | |
Capex per Share |
(1.68) | (1.11) | (1.20) | (1.16) | |
Free Cash Flow per Share |
4.37 | 2.90 | 2.49 | 2.43 | |
Cash per Share |
56.51 | 58.04 | 60.51 | 62.15 | |
Shareholders Equity per Share |
273.40 | 254.15 | 268.22 | 283.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
273.40 | 254.15 | 268.22 | 283.91 | |
Free Cash Flow |
119.10 | 78.20 | 66.60 | 65.20 | |
Working Capital |
2,389.20 | 2,025.10 | 2,059.20 | 2,109.50 | |
Capital Expenditures |
(45.80) | (29.90) | (32.10) | (31.20) | |
Net Current Asset Value |
(216.70) | 3.40 | (57.60) | (101.50) | |
EV/EBIT |
172.31 | 123.95 | 141.53 | 0.00 | |
Capex to Sales |
0.07 | 0.05 | 0.05 | 0.05 | |
Price to Operating Income |
179.46 | 130.23 | 149.34 | 0.00 | |
| Other line items | |||||
Average Receivables |
456.55 | 425.45 | 455.85 | 443.65 | |
Average Payables |
125.65 | 135.50 | 141.40 | 131.15 | |
Average Inventory |
750.35 | 780.30 | 789.70 | 783.55 | |
Average Assets |
9,970.30 | 9,658.45 | 10,233.05 | 10,239.75 | |
Average Common Equity |
7,011.45 | 6,765.35 | 7,151.30 | 7,169.90 |
Columns are period end dates · fundamentals updated 6 Nov 2026